Kyle Kurpinski

Executive Director, Investments, Tencent Exploration Team

2022 - Current

● Investing in data-driven deep tech to improve human lives and planetary resiliency ● Focus areas include biotech, digital health, AI, robotics, agriculture, and more ● Notable investments: - Guardant Health (NASDAQ: GH) - Oscar Health (NYSE: OSCR) - Oxford Nanopore (LSE: ONT.L) - Metagenomi (NASDAQ: MGX) - GRAIL (acquired) - Atomwise - Color - Culture Biosciences - Karius - Locus Biosciences

Partner, Tencent Exploration Team

2016 - 2022

Senior Manager, Strategic Initiatives, Tencent Exploration Team

2015 - 2016

Board Observer

2023

Angel Investor

2018

Investments include: Arpeggio Biosciences, Helium Health, Locus Biosciences, and more

Board Observer

2017 - 2020

Board Observer (acting)

2018 - 2020

Executive Director, Master of Translational Medicine Program

2011 - 2015

● Built and directed a joint professional Master's program between UC Berkeley and UCSF ● Managed curriculum, projects, finances, recruiting, admissions, and more ● Grew program to ~30 students at steady state with a self-sustaining budget

Senior Product Development Engineer

2008 - 2011

● Led R&D of Class II medical devices for soft-tissue regeneration including peripheral nerves ● Expanded company's IP portfolio with multiple patent filings ● Helped secure early-stage financing including investments and grants

Author

2007 - 2010

Co-author of a humorous science fiction guide book: Kyle Kurpinski and Terry D. Johnson. How to Defeat Your Own Clone: And Other Tips for Surviving the Biotech Revolution. New York: Bantam Dell, 2010.

Graduate Student Researcher (PhD program)

2003 - 2008

● Conducted research spanning stem cells, tissue engineering, micro-/nano-fabrication, and more ● Published articles in PNAS, Nano Letters, Biomaterials, and more

Research Assistant

2002 - 2002

● Discovered mutation site of sex-linked genetic disease without samples from affected patients ● Published findings in the American Journal of Medical Genetics